Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Past use of metformin is associated with increased risk of myelodysplastic syndrome development in diabetes mellitus patients: a cross-sectional study of 54,869 patients

T. Hellou, G. Dumanis, S. Portugez, AP. Goncharov, E. Trodler, A. Stern, I. Carlebach, O. Kahlon, MA. Jwella, E. Nimer, A. Athamna, A. Berman, G. Segal, RK. Lerner

. 2025 ; 26 (1) : 45. [pub] 20250227

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25009794

BACKGROUND: Myelodysplastic Syndrome (MDS) is a devastating hematologic malignancy associated with advanced age. Diabetes Mellitus (DM) is one of the most common morbidities worldwide, with metformin serving as the first line therapy for several decades. However, the potential association between previous metformin use and the risk of developing MDS remains uncertain. METHODS: This cross-sectional study addressed the possible association between prior metformin use in DM patients and the subsequent development of MDS. RESULTS: Data from 54,869 DM patients was retrieved from their medical records from a tertiary medical center. Of these, 20,318 patients had been exposed at some point in time to metformin, with 133 (0.7%) subsequently developing MDS. In contrast, among 34,551 DM patients with no prior exposure to metformin, only 154 (0.4%) developed MDS later in life. The Odds Ratio (OR) for MDS development amongst metformin users compared to the entire study population was 1.48 (95% CI 1.17-1.86; p = 0.001). A multivariate analysis adjusting for gender, age, congestive heart failure and chronic kidney disease, past exposure to metformin remained an independent risk factor for MDS development (OR = 1.6, 95% CI 1.26-2.03; p < 0.001). CONCLUSION: Previous exposure to metformin amongst DM patients is associated with an increased risk for MDS development later in life. This is a preliminary, cross-sectional study that show that larger studies in variable MDS patient populations are warranted.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25009794
003      
CZ-PrNML
005      
20250429135449.0
007      
ta
008      
250415s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s40360-025-00882-7 $2 doi
035    __
$a (PubMed)40016854
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Hellou, Tamer $u Hematology Division, Chaim Sheba Medical Center, Ramat Gan, Israel $u Faculty of Health Science and Medicine, Tel-Aviv University, Tel-Aviv, Israel
245    10
$a Past use of metformin is associated with increased risk of myelodysplastic syndrome development in diabetes mellitus patients: a cross-sectional study of 54,869 patients / $c T. Hellou, G. Dumanis, S. Portugez, AP. Goncharov, E. Trodler, A. Stern, I. Carlebach, O. Kahlon, MA. Jwella, E. Nimer, A. Athamna, A. Berman, G. Segal, RK. Lerner
520    9_
$a BACKGROUND: Myelodysplastic Syndrome (MDS) is a devastating hematologic malignancy associated with advanced age. Diabetes Mellitus (DM) is one of the most common morbidities worldwide, with metformin serving as the first line therapy for several decades. However, the potential association between previous metformin use and the risk of developing MDS remains uncertain. METHODS: This cross-sectional study addressed the possible association between prior metformin use in DM patients and the subsequent development of MDS. RESULTS: Data from 54,869 DM patients was retrieved from their medical records from a tertiary medical center. Of these, 20,318 patients had been exposed at some point in time to metformin, with 133 (0.7%) subsequently developing MDS. In contrast, among 34,551 DM patients with no prior exposure to metformin, only 154 (0.4%) developed MDS later in life. The Odds Ratio (OR) for MDS development amongst metformin users compared to the entire study population was 1.48 (95% CI 1.17-1.86; p = 0.001). A multivariate analysis adjusting for gender, age, congestive heart failure and chronic kidney disease, past exposure to metformin remained an independent risk factor for MDS development (OR = 1.6, 95% CI 1.26-2.03; p < 0.001). CONCLUSION: Previous exposure to metformin amongst DM patients is associated with an increased risk for MDS development later in life. This is a preliminary, cross-sectional study that show that larger studies in variable MDS patient populations are warranted.
650    _2
$a lidé $7 D006801
650    12
$a metformin $x terapeutické užití $x škodlivé účinky $7 D008687
650    12
$a myelodysplastické syndromy $x epidemiologie $x chemicky indukované $7 D009190
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a průřezové studie $7 D003430
650    _2
$a senioři $7 D000368
650    _2
$a lidé středního věku $7 D008875
650    12
$a hypoglykemika $x terapeutické užití $x škodlivé účinky $7 D007004
650    _2
$a diabetes mellitus $x epidemiologie $x chemicky indukované $7 D003920
650    _2
$a rizikové faktory $7 D012307
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a dospělí $7 D000328
655    _2
$a časopisecké články $7 D016428
700    1_
$a Dumanis, Guy $u Adelson School of Medicine, Ariel University, Ariel, 4070000, Israel
700    1_
$a Portugez, Shir $u Silesia Medical University, Katowice, Poland
700    1_
$a Goncharov, Aviv Philip $u Faculty of Medicine and Dentistry, Palacký University in Olomouc, Olomouc, 77900, Czech Republic
700    1_
$a Trodler, Eden $u Faculty of Medicine and Dentistry, Palacký University in Olomouc, Olomouc, 77900, Czech Republic
700    1_
$a Stern, Asaf $u Faculty of Medicine and Dentistry, Palacký University in Olomouc, Olomouc, 77900, Czech Republic
700    1_
$a Carlebach, Imanuel $u Faculty of Medicine and Dentistry, Palacký University in Olomouc, Olomouc, 77900, Czech Republic
700    1_
$a Kahlon, Omer $u Faculty of Medicine and Dentistry, Palacký University in Olomouc, Olomouc, 77900, Czech Republic
700    1_
$a Jwella, Maysan Abu $u Faculty of Medicine and Dentistry, Palacký University in Olomouc, Olomouc, 77900, Czech Republic
700    1_
$a Nimer, Ekram $u Faculty of Medicine, Kharkiv National Medical University, Kharkiv, Ukraine
700    1_
$a Athamna, Ahlam $u Internal Medicine Division, Sheba Medical Center, Ramat Gan, Israel
700    1_
$a Berman, Aya $u Dan Petah-Tikvah District at Clalit Health Service, Petah-Tikvah, Israel
700    1_
$a Segal, Gad $u Faculty of Health Science and Medicine, Tel-Aviv University, Tel-Aviv, Israel. gad.segal@sheba.health.gov.il $u Education Authority, Chaim Sheba Medical Center, Tel-Hashomer, Ramat Gan, Israel. gad.segal@sheba.health.gov.il
700    1_
$a Lerner, Reut Kassif $u Faculty of Health Science and Medicine, Tel-Aviv University, Tel-Aviv, Israel $u Department of Pediatric Intensive Care, The Edmond and Lily Safra Children's Hospital, at Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel
773    0_
$w MED00195156 $t BMC pharmacology & toxicology $x 2050-6511 $g Roč. 26, č. 1 (2025), s. 45
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40016854 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429135444 $b ABA008
999    __
$a ok $b bmc $g 2311279 $s 1246875
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 26 $c 1 $d 45 $e 20250227 $i 2050-6511 $m BMC pharmacology & toxicology $n BMC Pharmacol Toxicol $x MED00195156
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Možnosti archivace